share_log

The Recent 21% Gain Must Have Brightened CEO Bozhou Zhang's Week, Chaoju Eye Care Holdings Limited's (HKG:2219) Most Bullish Insider

The Recent 21% Gain Must Have Brightened CEO Bozhou Zhang's Week, Chaoju Eye Care Holdings Limited's (HKG:2219) Most Bullish Insider

最近21%的漲幅一定讓朝聚眼科(臨時代碼:2219)的CEO張博洲一週更加光明,這是該公司內部最看好的人。
Simply Wall St ·  10/01 02:37

Key Insights

關鍵見解

  • Insiders appear to have a vested interest in Chaoju Eye Care Holdings' growth, as seen by their sizeable ownership
  • 53% of the business is held by the top 5 shareholders
  • Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
  • 從超聚眼部護理控股公司的龐大所有權來看,業內人士似乎對潮聚眼部護理控股的增長有既得利益
  • 53% 的業務由前五名股東持有
  • 所有權研究以及分析師預測數據有助於更好地了解股票的機會

Every investor in Chaoju Eye Care Holdings Limited (HKG:2219) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 51% to be precise, is individual insiders. Put another way, the group faces the maximum upside potential (or downside risk).

潮聚眼科保健控股有限公司(HKG: 2219)的每位投資者都應該知道最強大的股東群體。持有公司股份最多的集團是個人內部人士,準確地說約爲51%。換句話說,該集團面臨最大的上行潛力(或下行風險)。

Clearly, insiders benefitted the most after the company's market cap rose by HK$431m last week.

顯然,上週該公司的市值上漲了4.31億港元之後,內部人士受益最大。

Let's delve deeper into each type of owner of Chaoju Eye Care Holdings, beginning with the chart below.

讓我們從下圖開始,深入研究朝聚眼科控股的每種類型的所有者。

big
SEHK:2219 Ownership Breakdown October 1st 2024
SEHK: 2219 所有權明細 2024 年 10 月 1 日

What Does The Institutional Ownership Tell Us About Chaoju Eye Care Holdings?

關於朝聚眼科控股,機構所有權告訴我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。

We can see that Chaoju Eye Care Holdings does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Chaoju Eye Care Holdings' historic earnings and revenue below, but keep in mind there's always more to the story.

我們可以看到,朝聚眼保健控股確實有機構投資者;他們持有該公司很大一部分股票。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。當多家機構擁有一隻股票時,總是存在處於 「擁擠交易」 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到超聚眼部護理控股的歷史收益和收入,但請記住,故事總是有更多內容。

big
SEHK:2219 Earnings and Revenue Growth October 1st 2024
SEHK: 2219 2024 年 10 月 1 日收益和收入增長

Hedge funds don't have many shares in Chaoju Eye Care Holdings. With a 14% stake, CEO Bozhou Zhang is the largest shareholder. The second and third largest shareholders are Orchid Asia Group Management, Ltd. and Xiaoli Zhang, with an equal amount of shares to their name at 12%. Interestingly, the third-largest shareholder, Xiaoli Zhang is also a Member of the Board of Directors, again, indicating strong insider ownership amongst the company's top shareholders.

對沖基金在朝聚眼科保健控股的股份不多。首席執行官張伯洲持有14%的股份,是最大股東。第二和第三大股東是蘭花集團管理有限公司和張曉麗,持有與他們同等數量的股份,爲12%。有趣的是,第三大股東張曉麗也是董事會成員,這再次表明公司最大股東擁有強大的內部所有權。

Our research also brought to light the fact that roughly 53% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.

我們的研究還揭示了這樣一個事實,即該公司約有53%的股份由前五名股東控制,這表明這些所有者對業務具有重大影響。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。有相當數量的分析師在報道該股,因此了解他們對未來的總體看法可能很有用。

Insider Ownership Of Chaoju Eye Care Holdings

朝聚眼科保健控股的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

不同國家對內部人員的定義可能略有不同,但董事會成員總是計算在內。公司管理層經營業務,但首席執行官將向董事會負責,即使他或她是董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

It seems that insiders own more than half the Chaoju Eye Care Holdings Limited stock. This gives them a lot of power. So they have a HK$1.2b stake in this HK$2.4b business. Most would be pleased to see the board is investing alongside them. You may wish todiscover (for free) if they have been buying or selling.

內部人士似乎擁有超聚眼科保健控股有限公司一半以上的股票。這賦予了他們很大的力量。因此,他們在這項24億港元的業務中擁有12億港元的股份。大多數人會很高興看到董事會與他們一起投資。您可能希望(免費)了解他們是否在買入或賣出。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a 26% stake in Chaoju Eye Care Holdings. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

公衆通常是個人投資者,持有朝聚眼科控股26%的股份。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。

Private Equity Ownership

私募股權所有權

With an ownership of 12%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私募股權公司擁有12%的所有權,可以在制定以價值創造爲重點的公司戰略方面發揮作用。有時我們會看到私募股權長期存在,但總的來說,它們的投資期限較短,而且顧名思義,對上市公司的投資並不多。一段時間後,他們可能會考慮出售資本並將其重新部署到其他地方。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 1 warning sign for Chaoju Eye Care Holdings you should be aware of.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。一個很好的例子:我們發現了朝聚眼科控股的1個警告信號,你應該注意。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但歸根結底,決定這家企業所有者的表現的是未來,而不是過去。因此,我們認爲最好看一下這份免費報告,該報告顯示了分析師是否預測了更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論